Eli Lilly stock was falling early Thursday even as the drugmaker posted first-quarter earnings that beat analysts’ ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

Pfizer ( ($PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Pfizer (PFE) has been the focus of ...

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.71, a high ...

Goldman Sachs analyst Asad Haider maintained their bullish stance on the stock, giving it a Buy rating on April 8. The ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

With a market cap of $717 billion, Eli Lilly (LLY) is one of the world’s largest pharmaceutical companies. Lilly is ...

Goldman Sachs has been deepening its investments in generative artificial intelligence. CEO David Solomon has said the bank's AI tools will "scale and transform our engineering abilities." ...

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.

We recently published a list of 10 Dirt Cheap Stocks To Invest In Now. In this article, we are going to take a look at where ...